Prebiotic Treatment in People with Schizophrenia

精神分裂症患者的益生元治疗

• 批准号: 10448075
• 负责人: ROBERT W BUCHANAN
• 金额: $ 16.75万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-15 至 2022-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10448075
• 关键词: Acetates; Administrative Supplement; Affect; Bacteria; Behavior; Biological; Brain; Butyrates; Consent; Data; Development; Dietary Fiber; Disease; Double-Blind Method; Ensure; Funding; Grant; Growth; Immune system; Impaired cognition; Impairment; Inflammatory; Intervention; Inulin; Lead; Light; Measures; Metabolic; Multiple Abnormalities; Participant; Patient Recruitments; Personal Satisfaction; Pharmacology; Placebos; Preparation; Production; Propionates; Randomized; Randomized Clinical Trials; Schizophrenia; Serum; Specific qualifier value; Symptoms; Therapeutic; U-Series Cooperative Agreements; United States National Institutes of Health; Volatile Fatty Acids; cognitive function; design; effective therapy; functional outcomes; gut bacteria; gut microbiota; immune system function; immunoregulation; microorganism; novel strategies; prebiotics; recruit

PROJECT SUMMARY People with schizophrenia have a broad range of cognitive impairments, which are major determinants of the poor functional outcome observed in people with this disorder. Unfortunately, pharmacological and non- pharmacological interventions have limited benefits for these impairments. In the absence of effective treatments, cognitive impairments remain a critical unmet therapeutic need, and the development of novel approaches for their treatment remains a central therapeutic challenge. Over the past 10 years, considerable evidence has emerged to suggest that the gut microbiota has significant effects on brain development and behavior, in part, through the regulation of immune system function. The gut microbiota affects immune system function through the production of short chain fatty acids (SCFAs) and other mechanisms. There are three major SCFAs: butyrate, propionate, and acetate, of which, butyrate appears to have the most pronounced effects on the immune system. Prebiotics are dietary fibers that promote the growth or activity of gut microorganisms, which leads to enhanced well-being of the host; they have been shown to increase the activity of multiple different bacteria species, including butyrate-producing bacteria. In light of the emerging evidence that suggests schizophrenia is characterized by multiple abnormalities of the immune system, which lead to a pro-inflammatory state, the proposed R61 project is designed to evaluate the hypothesis that prebiotic administration will lead to increased production of butyrate, through increased activity of butyrate-producing bacteria in the gut microbiota; the increase in serum butyrate levels will be associated with changes in cognitive function, symptoms, and metabolic measures. In the R61 project, we will conduct a 10-day, double- blind, placebo-controlled, randomized clinical trial (RCT) to determine if the prebiotic: Prebiotin (12g/day), an oligofructose-enriched inulin (OEI), alters the hypothesized biological signature, i.e., increases serum butyrate levels. We will use an inulin-challenge paradigm to assess the effect of OEI on serum butyrate levels. We are requesting an administrative supplement (PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements) to provide funds to enable us to complete our participant recruitment for the current R61 project, analyze the data and prepare our request for funding of the R33 project. We propose to use the supplemental funds to recruit an additional 11 participants, in order to ensure that we will have 8 more participants, who will complete the study. We would use months 7 and 8 of the proposed funding period to complete data checking and analyses and preparation of our request for R33 funding.

项目总结